en · de · es · pt
nad-notes.peptides9002.com › Blog › Background And Molecular Profile — Quick Reference

Background And Molecular Profile — Quick Reference

By Editorial Desk · published 2026-05-24 · last reviewed 2026-06-18 · Blog

This is a working overview of chronic hepatitis B, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.

Background and Molecular Profile

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Research History and Clinical Assessment

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Chemical classAcetylated peptideN-terminal acetyl group blocks aminopeptidase attack
Residue count28 amino acidsMatches the N-terminus of prothymosin alpha
Molecular massAbout 3,108 DaValue for the free, unmodified peptide
Isoelectric pointApproximately 4.2Acidic; net negative charge at neutral pH
Encoding genePTMAHuman gene for the precursor protein

分子身份与天然来源

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

Related pages on this site

Background and Mechanism of Action

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Further detail

=== Religion === Galloway has been outspoken in support of religious liberties. Though he has long stated that his religious beliefs are a private matter, Galloway was raised, and in 2016, said that he was a Roman Catholic Christian. In a 2013 interview, Galloway sparked controversy for saying as a Roman Catholic, he would not feel safe in an independent Scotland given the historically bigoted views harboured by many Scottish nationalists towards Catholics. At a 2012 rally, he said: "We stand for justice and haqq" and "A Muslim is somebody who is not afraid of earthly power but who fears only the Judgment Day. I'm ready for that, I'm working for that and it's the only thing I fear." In April 2012 Jemima Khan claimed Galloway had converted to Islam around 2000 and that his shahadah was performed in Kilburn, London. Galloway denied the claims, saying: "I have never attended any such ceremony in Kilburn, Karachi or Kathmandu. It is simply and categorically untrue." He went on to reiterate his position that religious beliefs are a "personal matter". His marriages to Dr Abu-Zayyad in 1994 and Rima Husseini in 2007 both took place in Muslim ceremonies. His wife since 2012, Putri Gayatri Pertiwi, is also Muslim. In March 2024, Galloway was sworn-in as an MP holding a copy of the Bible. In a Good Morning Britain interview, in April of the same year, Galloway stated he was "a practicing Roman Catholic".

In December 2022, Bukele tweeted that he believed that the country's 262 municipalities should be reduced to 50. He called it "absurd" ("absurdo") that El Salvador, around 8,100 square miles (21,000 km2) in size, had so many municipalities. Some lawyers and politicians criticized Bukele's proposed reduction as an attempt to consolidate power by gerrymandering. His allies supported the proposal, with some proposing a reduction in the number of Legislative Assembly seats. On 1 June 2023, during a speech commemorating his fourth year in office, Bukele announced that he would present two proposals to the Legislative Assembly. One sought to reduce the number of seats in the assembly from 84 to 60, and the other sought to reduce the number of municipalities from 262 to 44. Bukele justified the legislative reduction by saying that the legislature had 60 seats before the signing of the Chapultepec Peace Accords in 1992 that ended the Salvadoran Civil War, and the accords' only accomplishment was the addition of 24 seats to the legislature. About the municipal-reduction proposal, he stated that the 262 municipalities would retain their cultural identities and be classified as districts. The Legislative Assembly approved the proposal for legislative reductions on 7 June 2023, and approved the proposal for municipal reductions six days later. Both reductions became effective on 1 May 2024.

=== Gary === Gary (voiced by Tony Todd) is a Vortigaunt that suffered a brain injury sometime before the game. He is severed from the Vortessence, meaning he is cut off from the hivemind composed of his fellow Vortigaunts and has been "alone in [his] head". He joins Alyx as she rescues her father Eli from being sent to Nova Prospekt and later helps him get back to Russell's laboratory.

Sources: en.wikipedia.org

Background from the literature

At one week post-procedure, the patients resumed using the external vacuum tissue-expander for 10 hours daily, until the next fat grafting session; 2–5 outpatient procedures, 6–16 weeks apart, were required until the plastic surgeon and the patient were satisfied with the volume, form, and feel of the reconstructed breasts. The follow-up mammogram and MRI examinations found neither defects (necrosis) nor abnormalities (neoplasms). At six months post-procedure, the reconstructed breasts had a natural form, look, and feel, and the stable breast-volumes ranged 300–600 ml per breast. The post-procedure mammographies indicated normal, fatty breasts with well-vascularized fat, and few, scattered, benign oil cysts. The occurred complications included pneumothorax and transient cysts.

As a result of population growth in African-Caribbean regions of overseas France and immigration from North and sub-Saharan Africa to mainland France, sickle cell disease has become a major health problem in France. Sickle cell disease has become the most common genetic disease in the country, with an overall birth prevalence of one in 2,415 in mainland France, ahead of phenylketonuria (one in 10,862), congenital hypothyroidism (one in 3,132), congenital adrenal hyperplasia (one in 19,008) and cystic fibrosis (one in 5,014) for the same reference period.

Glycoprotein hormones, alpha polypeptide is a protein that in humans is encoded by the CGA gene. Thyroid-stimulating hormone (TSH) and the gonadotropin hormones human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) are heterodimers consisting of alpha and beta subunits (also called chains) that are associated non-covalently. The alpha subunits of these four human glycoprotein hormones are identical; however, their beta chains are unique and confer biological specificity. The protein encoded by this gene is the alpha subunit and belongs to the glycoprotein hormones alpha chain family. CGA levels are regulated by ELAVL1/HuR, and the small molecule Eltrombopag, which targets HuR/RNA interactions, has been shown to reduce CGA levels in human cultured cells.

Sources: en.wikipedia.org

Frequently asked questions

How does thymosin alpha 1 differ from thymosin fraction 5?

Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.

Which gene encodes the precursor protein?

The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.

Is the peptide found naturally in the human body?

It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.

Why are clinical results inconsistent?

Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.

Network